GWAG
NBIX icon

Garrett Wealth Advisory Group’s Neurocrine Biosciences NBIX Stock Holding History

Garrett Wealth Advisory Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-14
Closed -$1.26K – 437
2019
Q3 		$1.26K Buy
+14
New +$1.31K ﹤0.01% 671

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Garrett Wealth Advisory Group's NBIX Position: Q4 2019 in Review

Garrett Wealth Advisory Group sold out of Neurocrine Biosciences (NBIX) in Q4 2019, closing a stake of 14 shares — an estimated $1.26K sold.

Garrett Wealth Advisory Group first reported a position in NBIX in Q3 2019 and held it in 1 quarter. The position peaked at $1.26K in Q3 2019. 392 funds tracked by Wall St. Rank hold NBIX as of Q4 2019.

  • Garrett Wealth Advisory Group reported no remaining Neurocrine Biosciences position as of Q4 2019 after selling out during the quarter.
  • Garrett Wealth Advisory Group sold 14 Neurocrine Biosciences shares in Q4 2019, an estimated $1.26K.
  • Garrett Wealth Advisory Group first reported a position in Neurocrine Biosciences in Q3 2019 and held it in 1 quarter.
  • Garrett Wealth Advisory Group's Neurocrine Biosciences position peaked at $1.26K in Q3 2019.
  • 392 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2019.

Based on Garrett Wealth Advisory Group's 13F filing for Q4 2019, filed 28 Jan 2020.